Progesterone Receptor Negative Withdrawn Phase 1 Trials for Onalespib (DB06306)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Withdrawn1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02627430Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast CancerTreatment